The text starts here.

News Release

Jan 10, 2001

EISAI LAUNCHES UBITEN S -An Energy and Blood Circulation Improvement Product-

Tokyo (January 10, 2001) - Eisai Co., Ltd. of Tokyo (President and CEO: Haruo Naito) announced the launch on January 11th, of UBITEN S, a product promoting blood circulation through energy metabolism improvement.

UBITEN S contains as an active ingredient ubidecarenone which plays an important function in the production of the body's energy from three basic nutrients along with the vitamin B complex. The new product contains the prior product's ingredients, ubidecarenone and d-alpha-tocopherol acetate (natural type vitamin E) as well as the new ingredients riboflavin and nicotinic acid which are components of vitamin B complex. These ingredients serve to efficiently produce energy to improve heart function, alleviate palpitations, and shortness of breath.

The human body contains approximately 60 trillion cells and each individual cell requires energy for proper functioning. In our bodies the production of energy is necessary to maintain normal body heat and activity levels. When amounts of ubidecarenone are insufficient, the amount of energy supplied to the heart for the pumping of blood can be diminished. Thus the blood flow all over the body can be insufficient.

Ubidecarenone exists in organs that require high levels of energy such as the heart, kidneys, the liver and intestines. Ubidecarenone is replenished through food products such as beef, liver, and soy beans. Ubidecarenone is used and simultaneously assimilated by the body, but with age and improper diet deficiencies can arise.

UBITEN S provides the heart muscle with appropriate energy and can improve heart pump function, improve blood circulation, and can relieve swelling in the legs which can occur after long periods of standing.

In comparison to the previously sold product, each daily dosage now costs 25 percent less and the product packaging has also been redesigned.

Eisai Co., Ltd. is a research-based human health care company which discovers, develops and markets products in more than 30 countries. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide health care system. The Company reported sales of $2.9 billion in fiscal 1999 with greater than 15 percent of sales spent for research and development.

For additional information about UBITEN S and Eisai's other consumer healthcare products, please contact Eisai's Consumer Hotline.

Toll Free Number (in Japan): 0120-161-454.
Monday-Friday 9 a.m. - 6 p.m.
Saturday/Sunday/Holiday 9 a.m. - 5 p.m.